JAGSNPHARM Intraday Analysis...

JAGSNPHARM Share Price

Open 39.00 Change Price %
High 39.00 1 Day -0.25 -0.65
Low 38.05 1 Week -0.75 -1.93
Close 38.10 1 Month 2.80 7.93
Volume 9780 1 Year -0.25 -0.65
52 Week High 47.80
52 Week Low 25.80
JAGSNPHARM Important Levels
Resistance 2 38.98
Resistance 1 38.62
Pivot 38.38
Support 1 37.58
Support 2 37.22
NSE INDIA Most Active Stocks
JPASSOCIAT 10.20 5.15%
SUZLON 15.70 0.64%
JINDALSTEL 80.20 3.48%
ADANIPOWER 37.85 2.30%
HINDALCO 177.00 3.48%
VEDL 244.40 3.52%
GMRINFRA 12.55 0.00%
BHEL 132.40 3.48%
POWERGRID 198.45 0.35%
NHPC 29.80 -0.50%
More..
NSE INDIA Top Gainers Stocks
RASOYPR 0.20 33.33%
FMNL 45.00 20.00%
INDOTHAI 25.05 19.86%
HOTELRUGBY 4.60 19.48%
OILCOUNTUB 52.05 17.89%
PANACEABIO 148.30 16.59%
ELGIRUBCO 55.95 15.96%
TRIL 437.90 15.42%
WEIZFOREX 244.90 14.81%
JINDCOT 16.85 14.63%
More..
NSE INDIA Top Losers Stocks
VKSPL 0.10 -33.33%
FCSSOFT 0.30 -14.29%
SPYL 1.00 -13.04%
NAKODA 0.40 -11.11%
UNITEDTEA 303.95 -8.55%
AGARIND 332.80 -7.14%
ASIL 0.70 -6.67%
CELESTIAL 21.30 -6.17%
KRIDHANINF 57.75 -6.02%
SUNDARAM 4.05 -5.81%
More..

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM)

JAGSNPHARM Technical Analysis 4
As on 18th Jan 2017 JAGSNPHARM Share Price closed @ 38.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 36.89 & Strong Buy for SHORT-TERM with Stoploss of 35.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
JAGSNPHARM Target for January
1st Target up-side 36.8
2nd Target up-side 38.73
3rd Target up-side 40.66
1st Target down-side 31.3
2nd Target down-side 29.37
3rd Target down-side 27.44
Jagsonpal Pharmaceuticals Limited ( NSE INDIA Symbol : JAGSNPHARM )
Sector : Pharmaceuticals - Formulations And Other Stocks in Same Sector
JAGSNPHARM
38.10 -0.25 (-0.65 %)
LT : Buy
ST : Strong Buy
AMRUTANJAN
594.35 -12.30 (-2.03 %)
LT : Strong Buy
ST : Buy
JAGSNPHARM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
JAGSNPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals - Formulations
Industry
Offical website
JAGSNPHARM Address
JAGSNPHARM
N/A
Interactive Technical Analysis Chart Jagsonpal Pharmaceuticals Limited ( JAGSNPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Jagsonpal Pharmaceuticals Limited
JAGSNPHARM Business Profile
Jagson Pharma is in the Pharmaceuticals - Formulations sector. Jagsonpal Pharmaceuticals (JAGSONPH) is a pharmaceutical company producing drugs and formulations. The company was incorporated in 1978 as a private limited company and went public in 1986. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It focuses on several therapeutic groups like anti-arthritics, anti-inflammatories, analgesics, anti-spasmodics, progesterones, anabolic steroids, anesthetics and anti-fungals. Top selling brands include Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap SR. The company manufactures active pharmaceutical ingredients (APIs) like Allylestrenol, Disulfiram, Tolnaftate, ..etc. The bulk drug range includes dextropropoxyphene HCl, tolnaftate, dextropropoxyphene napsylate and thiopental sodium. The manufacturing facility in Delhi is WHO and GMP-certified for the production of various dosage forms and bulk drugs and intermediates. The company also maintains a number of dedicated contract manufacturing facilities around the globe. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe. The distribution network in India is comprised of over 1,500 authorized stockists who are serviced by depots. The products are retailed at over 125,000 pharmacies. The company is represented by 2,500 agents worldwide and has offices in three continents. The company`s operations span Russia, USA, Brazil, Ukraine, Sri Lanka, Cameroon, Argentina, Thailand, Germany, Switzerland, Korea, Egypt and Vietnam. The company has a sales office in New York through which it services North and Latin American clients and in Belarus, it has an operation center with a sales and distribution team. The current market capitalisation stands at Rs 23.71 crore.The company has reported a standalone sales of Rs 36.79 crore and a Net Profit of Rs 0.01 crore for the quarter ended Sep 2013. The company management includes R P S Kochhar - Chairman & Managing Director, S K Goyal - Director, Govind Deo - Additional Director, Bharat Sinh - Additional Director, Ishpal Singh Ghai - Additional Director. It is listed on the BSE with a BSE Code of 507789 and the NSE with an NSE Code of JAGSNPHARM. Its Registered office is at T-210 J, Shahpur Jat , New Delhi,Delhi - 110049.